Nexentis Technologies Inc. (NXTS) Stock Price & Analysis
Nexentis Technologies Inc. (NXTS) rose 2.38% to USD 1.72 as of September 8, 2026 at 06:58 UTC, according to Nexqual real-time market data.
NXTS last closed at USD 1.72; the session ranged USD 1.61–1.73 on volume of 10,136 shares. Market capitalization is —, with a 52-week range of USD 1.43–58.8 (NCM). Source: Nexqual, September 8, 2026 at 06:58 UTC.
Key Statistics (as of September 8, 2026 at 06:58 UTC)
| Price | USD 1.72 |
|---|---|
| Change | ▲ 2.38% (up) |
| Previous Close | USD 1.72 |
| Open | USD 1.72 |
| Day Range | USD 1.61 – 1.73 |
| 52-Week Range | USD 1.43 – 58.8 |
| Volume | 10,136 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (NXTS)
Nexqual's technical model rates NXTS "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:58 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.95 (neutral) |
| vs SMA50 | Below (USD 2.39) |
| MACD | -0.18 (negative) |
From Nexentis Technologies Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- MitoCareX currently has an application for registration of "MITOLINE™" mark in the United States.   Scope and Duration of Intellectual Property Protection   The area of patents and other intellectual property rights in the biopharmaceutical industry is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology.
- For this and other risks related to our proprietary technology, inventions, improvements, and product candidates.   We also rely on trade secret protection for our confidential and proprietary information.
- The solutions are based on our proprietary blend of food acids combined with certain types of oxidizing agent-based sanitizers and in some cases with fungicides at low concentrations.
- These limitations have pushed MitoCareX to develop MITOLINE™ – a novel proprietary algorithm which outputs can be used for the generation of reliable 3D models for potentially all the 53 human mitochondrial proteins.   Mitochondrial carriers are directly linked to diverse types of malignancies (PMID 32783608) including lung cancer – the 2nd worldwide cancer in the world.
Partnerships
- By forming a temporary protective shield around the fresh produce we treat, our solutions make it difficult for pathogens to develop and potentially provide protection which also reduces cross-contamination.   On January 13, 2026, we entered into the SF Agreement with Voice Assist, and, for certain limited purposes set forth therein, Save Foods.
- Brand is a private company wholly owned by Brand (M.G.) Ltd., (a public company).   In Poland and Italy, Solterra Energy operates through Solterra in collaboration with Brand.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPRC | SciSparc Ltd. | USD 5.29 | ▼ 9.57% |
| TGL | Treasure Global Inc. | USD 2.42 | ▼ 2.81% |
| FRGT | Freight Technologies, Inc. | USD 1.07 | ▼ 10.83% |
| ACON | Aclarion, Inc. | USD 2.35 | ▲ 1.73% |
| PRFX | PRF Technologies Ltd. | USD 0.97 | ▼ 0.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:58 UTC. This page is informational and not investment advice.